Encompass Health Insider Lowered Holding By 26% During Last Year
Encompass Health Insider Lowered Holding By 26% During Last Year
From what we can see, insiders were net sellers in Encompass Health Corporation's (NYSE:EHC ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it.
据我们所见,在过去的12个月中,内部人士是Encomass Health Corporation(纽约证券交易所代码:EHC)的净卖家。也就是说,内部人士出售股票的数量比购买的数量还要多。
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
尽管我们认为股东不应干脆关注内幕交易,但我们认为完全忽视内幕交易是愚蠢的。
The Last 12 Months Of Insider Transactions At Encompass Health
Encompass Health 过去 12 个月的内幕交易
Over the last year, we can see that the biggest insider sale was by the Chief Medical Officer, Elissa Charbonneau, for US$577k worth of shares, at about US$69.58 per share. That means that even when the share price was below the current price of US$76.45, an insider wanted to cash in some shares. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. This single sale was just 26% of Elissa Charbonneau's stake. Elissa Charbonneau was the only individual insider to sell over the last year.
在过去的一年中,我们可以看到,最大的内幕出售是首席医疗官艾丽莎·夏邦诺,以每股约69.58美元的价格出售了价值57.7万美元的股票。这意味着,即使股价低于当前的76.45美元,内部人士也想套现一些股票。当内部人士以低于当前价格的价格出售时,这表明他们认为较低的价格是公平的。这让我们想知道他们如何看待最近(更高的)估值。但是,请注意,卖家可能有各种各样的卖出原因,因此我们不确定他们对股价的看法。此次出售仅占艾丽莎·夏邦诺股份的26%。艾丽莎·夏邦诺是去年唯一一位出售股票的内部人士。
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
您可以看到下图所示的去年的内幕交易(公司和个人)。通过点击下面的图表,你可以看到每笔内幕交易的确切细节!
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
如果你像我一样,那么你不会想错过这份业内人士正在收购的成长型公司的免费名单。
Does Encompass Health Boast High Insider Ownership?
Encompass Health 是否拥有很高的内部
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 1.3% of Encompass Health shares, worth about US$99m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
许多投资者喜欢查看公司内部人士拥有多少股份。通常,内部人士的所有权越高,内部人士长期建立公司的可能性就越大。内部人士拥有Encompass Health1.3%的股份,价值约9900万美元。当然,我们在其他地方看到了更高的内部所有权水平,但这些持股足以表明内部人士与其他股东之间的一致性。
So What Does This Data Suggest About Encompass Health Insiders?
那么,这些数据对Encompass Health Insiders
It doesn't really mean much that no insider has traded Encompass Health shares in the last quarter. We don't take much encouragement from the transactions by Encompass Health insiders. But it's good to see that insiders own shares in the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. While conducting our analysis, we found that Encompass Health has 1 warning sign and it would be unwise to ignore it.
上个季度没有内部人士交易过Encomass Health的股票,这并没有多大意义。我们并没有从Encomass Health内部人士的交易中得到太多鼓励。但很高兴看到内部人士拥有该公司的股份。因此,这些内幕交易可以帮助我们建立有关股票的论点,但也值得了解这家公司面临的风险。在进行分析时,我们发现Encomass Health有1个警告信号,忽略它是不明智的。
Of course Encompass Health may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,Encomass Health可能不是最好的买入股票。因此,您可能希望看到这个免费的高质量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。